In addition, AZD5991 shows enhanced efficacy against growth of MM and AML subcutaneous tumors when combined with agents that enhance Bim activity and/or Mcl-1-dependency, such as bortezomib or venetoclax. The gene discussed is BCL2L11; the disease is Miyoshi myopathy.